Learn more in our training program.
Join our membership network.
Attend our events and collaborate.
Add your voice to our policy matters.
Get involved in our genetic registry.
Donate to our cause.
The Latino Cancer Institute (TLCI) is a nationwide community and research network dedicated to solving the issues and burden of Latino cancer.
Cancer remains one of the leading causes of death among Hispanics/Latinos in the U.S., accounting for approximately 17% of deaths. At the same time, federal support for health equity and cancer disparities research is facing unprecedented cuts—making community-driven leadership more critical than ever.
Cancer affects Latino men and women differently, requiring targeted approaches. Among Latinas, breast cancer remains the most commonly diagnosed cancer and the leading cause of cancer death, while cervical cancer continues to pose a serious and largely preventable threat.
For Latino men, the challenges are equally urgent. Lung cancer remains the leading cause of cancer death, and Latino men are more likely to be diagnosed with prostate, colorectal, liver, and testicular cancers—often at later stages.
Our mission. The Latino Cancer Institute works to reduce the burden of cancer in Latino communities by convening expertise, amplifying community-informed research, and advocating for equitable cancer care. As public funding becomes more uncertain, philanthropic support helps ensure Latino communities are not left out of cancer research, policy discussions, or solutions. Learn more about our work.
For over 20 years, Founder Ysabel Duron has played a vital role in bringing together those dedicated to making a difference in the Latino cancer landscape. From cancer community workers and caregivers to international medical researchers and policymakers, Ysabel has forged important alliances in a field crowded with many competing interests and agendas.
It takes a savvy insider who has traveled this terrain far and wide to help the Latino cancer community at-large continue changing the landscape. TLCI offers the definitive road map.
The Latino Cancer Institute acts as a network for agencies, linking members to share knowledge and best practices. Connecting colleagues, peers and institutions is critical to The Institute’s ongoing mission to amplify and disseminate outstanding work in the cancer arena, and to support one another.
The Latino Cancer Institute provides opportunities to network, learn and collaborate with stakeholders in the cancer landscape including Latino cancer researchers.
The Latino Cancer Institute convenes leading experts, advocates, and community voices to examine critical cancer issues affecting Latino communities and to surface actionable insights. Recordings from TLCI’s recent Forums are now available—free to watch—covering cancer risks, disparities, and lived experiences across Latino women, men, children, and families. Watch Forum videos.
The Latino Cancer Institute leverages our united voice at the national table to advance Latino cancer concerns including education, services, funding, and research. Our aim is to be heard, understood and included in any proposed policy.
As a nonprofit organization, we rely on philanthropy and grants in our mission to support other agencies. Your funding allows us to continue the development of new programs and tools we can share with those making a difference in the lives of Latino cancer patients, survivors, and their caregivers.
A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer. Researchers say the findings are promising but not yet proof, and clinical trials are now being planned to test whether these drugs could help prevent breast cancer.
Supplements are often marketed as shortcuts to better health, but for many older adults, the real issue is whether they have a specific deficiency. Vitamins like B12 and D can play an important role when levels are low, while protein may be one of the most overlooked nutrients for maintaining strength and independence. More isn’t always better, though—some supplements can cause harm or interact with medications.
Scientists have successfully tested an AI-designed universal coronavirus vaccine in humans for the first time, finding it to be safe and well tolerated. The vaccine generated immune responses against multiple coronaviruses, including SARS-CoV-2, SARS, and related bat viruses with pandemic potential. By targeting features shared across an entire virus family, it aims to provide protection even as viruses evolve.
Scientists have identified genetic variants that may make some people less responsive to GLP-1 drugs used to treat Type 2 diabetes. Roughly 10% of the population carries these variants, which appear to cause a mysterious form of "GLP-1 resistance." In several clinical trials, carriers were significantly less likely to reach healthy blood sugar targets while taking GLP-1 medications.
For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic tumors—something many scientists once thought couldn't be done. In a major clinical trial, the treatment nearly doubled survival for patients with advanced disease and reduced the risk of death by 60%.
Scientists have uncovered a surprising new way the immune system fights cancer, overturning a core belief that has guided immunology for decades. The research found that when cancer cells shut down a key immune-recognition molecule called MHC I—a common trick used to hide from “killer” T cells—they can actually become more vulnerable to attack by a different group of immune cells known as CD4+ “helper” T cells.
